Mersana Therapeutics(MRSN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 - Dose escalation advancing in Phase 1 clinical trial of XMT-2056 - Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., November 13, 2024 – Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (AD ...